Latest insights

Malgorzata Kluba, Rudi Van Den Eynde, Oncology, Equities

World Cancer Day 2023

And we would rather not have to go through this – which would mean we won the battle and cancer is curable.
  • Equities, Geoffroy Goenen, Value vs Growth

    The second step of the waltz

    Despite a fairly significant rally beginning in October, European equity markets, battered by major outflows since the start of the crisis in Ukraine, recorded a correction over the year 2022 (-9.5%). Although European equities finished the year on a relative outperformance compared with the United States (-13.4%) and emerging markets (-15.1%)1, the year was still a source of concern for investors, who are now asking questions about what may arise in 2023.
  • SRI, SFDR

    Stay on Top of SFDR

    Sustainable Finance Disclosures Regulation (SFDR), mandatory ESG disclosure obligations, was introduced by the European Union to improve transparency in the market for sustainable investment.
11 results found
  • Rudi Van Den Eynde
Show me
  • Topic
  • Theme
  • Publication
  • Author
Show me
  • Topic
  • Theme
  • Publication
from
  • Author
11 results found
  • Rudi Van Den Eynde
Malgorzata Kluba, Rudi Van Den Eynde, Oncology, Equities

World Cancer Day 2023

And we would rather not have to go through this – which would mean we won the battle and cancer is curable.
Outlook 2023, Rudi Van Den Eynde

Building a New World: Thematic Investments

In the United States Antonín Dvořák composed the New World Symphony in 1893 and Neil Armstrong took it on a cassette to the moon. Rudi Van den Eynde takes it global, presenting us a New World of long-term trends.
Oncology, Video, Rudi Van Den Eynde

Be part of the solution: investing in oncology companies

Cancer remains the second-leading cause of death globally. As the incidence of cancer increases with age, its prevalence is unfortunately linked to the ageing of the world's population.
Equities, Rudi Van Den Eynde

Artificial intelligence: a revolution is underway

Artificial intelligence (AI) is about to revolutionise the diagnosis, surveillance and treatment of several diseases. Driven by technological development and research progress, growth in the AI market will surge over the next decade. An explanation.
Podcast, Equities, Rudi Van Den Eynde

An update on Thematic Equity

Covid-19 Series - Podcast #6 :With our guests Rudi Van den Eynde, Head of Thematic Global Equity and Renato Guerriero, Global Head of Distribution & Member of the Executive Committee - Group Strategic Committee
Q&A, Health Care, Rudi Van Den Eynde

Biotech investing: is there a doctor in the house?

Rudi Van den Eynde, Head of Thematic Global Equity at Candriam, answers investors’ questions about a sector where depth of specialist knowledge is a prerequisite to consistent stock selection success.

Find it fast

Get information faster with a single click

Get insights straight to your inbox